head and neck cancer

Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test
Endpoints
MaxiVAX
cancer
vaccines
cancer vaccines
solid tumors
head and neck cancer
Flag link:
Merck's Keytruda wins FDA approval to treat head and neck cancer
Merck's Keytruda wins FDA approval to treat head and neck cancer
Yahoo/Reuters
Merck
FDA
head and neck cancer
Flag link:
BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop
BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flop
Fierce Pharma
Bristol-Myers Squibb
head and neck cancer
Opdivo
Yervoy
Flag link:
FDA promises speedy review on moving Merck's Keytruda up as first-line head and neck cancer therapy
FDA promises speedy review on moving Merck's Keytruda up as first-line head and neck cancer therapy
Endpoints
Merck
Keytruda
FDA
head and neck cancer
priority review
Flag link:
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
Fierce Pharma
AstraZeneca
Imfinzi
head and neck cancer
clinical trials
Flag link:
ESMO: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer
ESMO: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer
Fierce Pharma
Merck
head and neck cancer
Keytruda
Flag link:
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Huge Oral Mucositis Market
Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Huge Oral Mucositis Market
CP Wire
Innovation Pharmaceuticals
severe oral mucositis
Brilacidin
head and neck cancer
Flag link:
Rakuten’s CEO raises $150M to fund his biotech outfit Aspyrian's cancer photoimmunotherapies
Rakuten’s CEO raises $150M to fund his biotech outfit Aspyrian's cancer photoimmunotherapies
Fierce Biotech
Rakuten Aspyrian
photoimmunotherapy
head and neck cancer
Flag link:
CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial
CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial
CP Wire
Cel-Sci
Multikine
head and neck cancer
Flag link:
CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial
Cel-Sci
Multikine
head and neck cancer
Flag link:
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
CP Wire
Immunicum
clinical trials
ilixadencel
head and neck cancer
non-small cell lung cancer
gastric cancer
Flag link:
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Flag link:
Innovation Pharmaceuticals Reports on Successful Phase II Trial of Brilacidin-OM for Oral Mucositis
Innovation Pharmaceuticals Reports on Successful Phase II Trial of Brilacidin-OM for Oral Mucositis
CP Wire
Innovation Pharmaceuticals
Brilacidin-OM
head and neck cancer
severe oral mucositis
Flag link:
On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
Endpoints
Regeneron
ISA
cervical cancer
head and neck cancer
cemiplimab
Flag link:
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
Flag link:
FDA gives OK, Cel-Sci clinical hold finally lifted
FDA gives OK, Cel-Sci clinical hold finally lifted
BioPharma Dive
FDA
Cell-Sci
Multikine
clinical trials
head and neck cancer
Flag link:
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
Xconomy
Merck
Keytruda
head and neck cancer
Flag link:
Bristol-Myers' Opdivo racks up latest NICE rejection, this time in head and neck cancer
Bristol-Myers' Opdivo racks up latest NICE rejection, this time in head and neck cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
NICE
head and neck cancer
Flag link:
Bristol's Bid To Get Ahead In Head And Neck
Bristol's Bid To Get Ahead In Head And Neck
Seeking Alpha
Bristol-Myers Squibb
head and neck cancer
Opdivo
Keytruda
Merck
Flag link:
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
Endpoints
FDA
AstraZeneca
durvalumab
clinical trials
head and neck cancer
Flag link:

Pages